ATE289801T1 - Verabreichungssystem für wasserunlösliche arzneistoffe - Google Patents

Verabreichungssystem für wasserunlösliche arzneistoffe

Info

Publication number
ATE289801T1
ATE289801T1 AT99965336T AT99965336T ATE289801T1 AT E289801 T1 ATE289801 T1 AT E289801T1 AT 99965336 T AT99965336 T AT 99965336T AT 99965336 T AT99965336 T AT 99965336T AT E289801 T1 ATE289801 T1 AT E289801T1
Authority
AT
Austria
Prior art keywords
water
drug
delivery system
administration system
present
Prior art date
Application number
AT99965336T
Other languages
English (en)
Inventor
S Esmail Tabibi
Emmanuel I Ezennia
B Rao Vishnuvajjala
Shanker Gupta
Original Assignee
Us Health
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Us Health filed Critical Us Health
Application granted granted Critical
Publication of ATE289801T1 publication Critical patent/ATE289801T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4192—1,2,3-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1277—Preparation processes; Proliposomes
    • A61K9/1278—Post-loading, e.g. by ion or pH gradient

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dispersion Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT99965336T 1998-12-22 1999-12-22 Verabreichungssystem für wasserunlösliche arzneistoffe ATE289801T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11342398P 1998-12-22 1998-12-22
PCT/US1999/030631 WO2000037050A1 (en) 1998-12-22 1999-12-22 Water-insoluble drug delivery system

Publications (1)

Publication Number Publication Date
ATE289801T1 true ATE289801T1 (de) 2005-03-15

Family

ID=22349322

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99965336T ATE289801T1 (de) 1998-12-22 1999-12-22 Verabreichungssystem für wasserunlösliche arzneistoffe

Country Status (7)

Country Link
EP (1) EP1140017B9 (de)
JP (1) JP2002532535A (de)
AT (1) ATE289801T1 (de)
AU (1) AU773618B2 (de)
CA (1) CA2356959C (de)
DE (1) DE69924004T2 (de)
WO (1) WO2000037050A1 (de)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7193084B2 (en) 2000-12-22 2007-03-20 Baxter International Inc. Polymorphic form of itraconazole
US8067032B2 (en) 2000-12-22 2011-11-29 Baxter International Inc. Method for preparing submicron particles of antineoplastic agents
US7037528B2 (en) 2000-12-22 2006-05-02 Baxter International Inc. Microprecipitation method for preparing submicron suspensions
US6977085B2 (en) 2000-12-22 2005-12-20 Baxter International Inc. Method for preparing submicron suspensions with polymorph control
US6884436B2 (en) 2000-12-22 2005-04-26 Baxter International Inc. Method for preparing submicron particle suspensions
US9700866B2 (en) 2000-12-22 2017-07-11 Baxter International Inc. Surfactant systems for delivery of organic compounds
US6872715B2 (en) 2001-08-06 2005-03-29 Kosan Biosciences, Inc. Benzoquinone ansamycins
US20060003012A9 (en) 2001-09-26 2006-01-05 Sean Brynjelsen Preparation of submicron solid particle suspensions by sonication of multiphase systems
CN1558755A (zh) 2001-09-26 2004-12-29 ���ع��ʹ�˾ 通过分散和除去溶剂或液相制备亚微米大小的纳米颗粒
US7112340B2 (en) 2001-10-19 2006-09-26 Baxter International Inc. Compositions of and method for preparing stable particles in a frozen aqueous matrix
WO2004096229A1 (ja) * 2003-04-30 2004-11-11 Dainippon Sumitomo Pharma Co., Ltd. 溶液医薬組成物
US20050020534A1 (en) * 2003-05-30 2005-01-27 Kosan Biosciences, Inc. Method for treating diseases using HSP90-inhibiting agents in combination with antimetabolites
US20050256097A1 (en) * 2004-05-11 2005-11-17 Kosan Biosciences, Inc. Pharmaceutical solution formulations containing 17-AAG
US20160106717A1 (en) 2004-09-24 2016-04-21 Gen Pharma Holdings LLC Cai-based systems and methods for the localized treatment of uveitis
WO2006037106A2 (en) * 2004-09-24 2006-04-06 Rfe Pharma Llc Carboxy-amido-triazoles for the localized treatment of ocular diseases
AU2013204198B2 (en) * 2005-02-18 2016-04-21 Abraxis Bioscience, Llc Combinations and modes of administration of therapeutic agents and combination therapy
US8735394B2 (en) 2005-02-18 2014-05-27 Abraxis Bioscience, Llc Combinations and modes of administration of therapeutic agents and combination therapy
BRPI0609509A2 (pt) 2005-03-30 2010-04-13 Conforma Therapeutics Corp composto ou um polimorfo, solvato, tautÈmero, enanciÈmero, pró-droga ou sal farmaceuticamente aceitável do mesmo, composição farmacêutica, e, uso do composto, polimorfo, solvato, tautÈmero, enanciÈmero, pró-droga ou sal farmaceuticamente aceitável
WO2008055386A1 (fr) * 2006-11-10 2008-05-15 Shenzhen Shengeryimei Biotech Co., Ltd. Composition pharmaceutique hydrosoluble pour injection de 17-allyl amino-17-déméthoxy geldanamycine (17-aag)
PE20081506A1 (es) 2006-12-12 2008-12-09 Infinity Discovery Inc Formulaciones de ansamicina
GB2451811A (en) 2007-08-09 2009-02-18 Ems Sa Delivery composition for solubilising water-insoluble pharmaceutical active ingredients
EP2525819B1 (de) * 2010-01-19 2018-06-06 Robert Coifman Immuntherapiezusammensetzungen und -behandlungsverfahren

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS55111469A (en) * 1979-02-19 1980-08-28 Kaken Pharmaceut Co Ltd Novel geldanamycin derivative, its preparation, and antitumor drug comprising it as active ingredient
FR2609631A1 (fr) * 1987-01-15 1988-07-22 Sanofi Sa Compositions liquides stables a base de bithionol
ES2087151T3 (es) * 1989-03-31 1996-07-16 Univ California Preparacion de composiciones complejas de liposomas y lipidos.
DE4125255A1 (de) * 1991-07-31 1993-02-04 Knoll Ag Prostaglandin e (pfeil abwaerts)1(pfeil abwaerts)-formulierung
AU688782B2 (en) * 1993-09-30 1998-03-19 Wyeth Rapamycin formulations for oral administration
GB9500116D0 (en) * 1995-01-05 1995-03-01 Ciba Geigy Ag Pharmaceutical compositions
CA2227205C (en) * 1995-07-21 2007-05-01 Constantia Gruppe Treatment and prevention of neoplasms with salts of aminoimidazole carboxamide and 5-amino or substituted amino 1,2,3-triazoles
US5877205A (en) * 1996-06-28 1999-03-02 Board Of Regents, The University Of Texas System Parenteral paclitaxel in a stable non-toxic formulation
WO1998053799A2 (en) * 1997-05-28 1998-12-03 Jenner Biotherapies, Inc. Immunogenic compositions
WO2000002534A1 (fr) * 1998-07-10 2000-01-20 Welfide Corporation Kit a preparer avant usage avec preparation contenant un medicament et solvant destine a cette fin

Also Published As

Publication number Publication date
AU773618B2 (en) 2004-05-27
WO2000037050A1 (en) 2000-06-29
EP1140017B1 (de) 2005-03-02
CA2356959C (en) 2009-03-31
EP1140017B9 (de) 2005-05-04
DE69924004D1 (de) 2005-04-07
EP1140017A1 (de) 2001-10-10
AU3127800A (en) 2000-07-12
JP2002532535A (ja) 2002-10-02
CA2356959A1 (en) 2000-06-29
DE69924004T2 (de) 2006-02-09

Similar Documents

Publication Publication Date Title
ATE289801T1 (de) Verabreichungssystem für wasserunlösliche arzneistoffe
AP1760A (en) Platinum derivative pharmaceutical formulations.
WO2004105702A3 (en) Foamable pharmaceutical compositions and methods for treating a disorder
ATE235895T1 (de) Arzneistoff-abgabesystem enthaltend eine festgepackte, feste arzneistoffbasis
AU2274201A (en) Compounds and compositions for delivering active agents
MY129350A (en) Aripiprazole oral solution
AU2001296865A1 (en) (5-(2-hydroxy-4-chlorobenzoyl) aminovaleric acid and salts thereof and compositions containing the same for delivering active agents
MXPA01008611A (es) Compuestos y composiciones para suministrar agentes activos.
NZ524138A (en) Cyanophenoxy carboxylic acid compounds and compositions for delivering active agents
ATE424810T1 (de) Ein hydrokolloid und einen celluloseether enthaltende tablette mit verzögerter freisetzung
BR9912694A (pt) Composto para preparar medicamento de administração pulmonar
MXPA03000820A (es) Compuestos terapeuticos de polianhidrido para suministro de farmacos.
ATE292453T1 (de) Antivirale arznei
AP2004003120A0 (en) Combined use of antitumor indolopyrrolocarbazole derivatives and other antitumor agent
IL151628A0 (en) Combination therapies with vascular damaging activity
IT1314185B1 (it) Composizione farmaceutica per somministrazione di sostanze attivescarsamente solubili in mezzi acquosi
DK1280558T3 (da) Halvfast indgivelsesvehikel og farmaceutiske sammensætninger
BR0112258A (pt) Sistema de entrega de droga para drogas pouco solúveis em água
UA89349C2 (uk) Таблетка без покриття, яка містить оланзапін, та спосіб її одержання
BRPI0413374A (pt) composições para liberação de base fraca por um perìodo estendido de tempo
CO4750645A1 (es) Metodo de preparacion de granulos que incorporan un medica- mento para uso farmaceutico
DK1144420T3 (da) Sulfaterede phosphatidylinositoler, fremgangsmåde til fremstilling heraf og anvendelser heraf
HK1048770A1 (zh) 组胺作为用於经粘膜或经皮传递的一种药物传递增强化合物的用途
TH64263A (th) สารรวมซึ่งประกอบรวมด้วยคอมบรีทาสแททิน (combretastatin) และตัวกระทำต้านมะเร็ง (anticancer)

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties